A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, Matsui M, Ikeno E, Hirono O, Miyawaki H, Yashiro Y, Nishiyama S, Arimoto T, Takahashi H, Shishido T, Miyashita T, Miyamoto T, Kubota I, CHERRY study investigators
Journal of cardiology · 133 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-09-01 · J Cardiol · vol. 70 · número 6 · págs. 537–544
- Editorial
- Elsevier BV
- Citado
- 177 citas · más que el 99% de estudios similares · 9.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Fatty Acid Research and Health · Lipoproteins and Cardiovascular Health · Eicosanoids and Hypertension Pharmacology
- Palabras clave
- Medicine, Internal medicine, Eicosapentaenoic acid, Cardiology, Percutaneous coronary intervention, Intravascular ultrasound, Myocardial infarction
- MeSH
- humans, quinolines, eicosapentaenoic acid, hydroxymethylglutaryl-coa reductase inhibitors, combined modality therapy, aged, middle aged, female, male, acute coronary syndrome, plaque, atherosclerotic, angina, stable, percutaneous coronary intervention
17 autores
- Tetsu Watanabe🇯🇵 · autor de correspondenciaYamagata University
- Kaoru Ando🇯🇵Yamagata University
- Hyuma Daidoji🇯🇵Yamagata Prefectural Central Hospital
- Yoichiro Otaki🇯🇵Yamagata University
- Shigeo Sugawara🇯🇵Nihonkai General Hospital
- Motoyuki Matsui🇯🇵Yamagata Prefectural Central Hospital
- Eiichiro Ikeno
- Osamu Hirono🇯🇵Yamagata Prefectural Shinjo Hospital
- Hiroshi Miyawaki🇯🇵Yamagata City Hospital Saiseikan
- Yoshinori Yashiro🇯🇵Yamagata University
- Satoshi Nishiyama🇯🇵Yamagata University
- Takanori Arimoto🇯🇵Yamagata University
- Hiroki Takahashi🇯🇵Yamagata University
- Tetsuro Shishido🇯🇵Yamagata University
- Takehiko Miyashita🇯🇵Tohoku Medical and Pharmaceutical University Hospital
- Takuya Miyamoto🇯🇵Yamagata University
- Isao Kubota🇯🇵Yamagata University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
There is a residual risk of coronary heart disease (CHD) despite intensive statin therapy for secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by the addition of eicosapentaenoic acid (EPA) to high-dose pitavastatin (PTV).
Methods
We enrolled 193 CHD patients who underwent percutaneous coronary intervention (PCI) in six hospitals. Patients were randomly allocated to the PTV group (PTV 4mg/day, n=96) or PTV/EPA group (PTV 4mg/day and EPA 1800mg/day, n=97), and prospectively followed for 6-8 months. Coronary plaque volume and composition in nonstenting lesions were analyzed by integrated backscatter intravascular ultrasound (IB-IVUS).
Results
The PTV/EPA group showed a greater reduction in total atheroma volume compared to PTV group. IB-IVUS analyses revealed that lipid volume was significantly decreased during follow-up period in only PTV/EPA group. The efficacy of additional EPA therapy on lipid volume reduction was significantly higher in stable angina pectoris (SAP) patients compared to acute coronary syndrome patients. EPA/AA ratio was significantly improved in PTV/EPA group compared to PTV group. There was no significant difference in the incidence of major adverse cardiovascular events and side effects.
Conclusions
Combination EPA/PTV therapy significantly reduced coronary plaque volume compared to PTV therapy alone. Plaque stabilization was also reinforced by EPA/PTV therapy in particular SAP patients. The addition of EPA is a promising option to reduce residual CHD risk under intensive statin therapy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.